JAK2 and myeloid sarcoma: Among gene polymorphisms,combination of variants within the non-HLA JAK2,IL10RB, GBP1, PIAS, IL10 genes and some othersas well as HLA genes have shown significant associationwith non-responding status of MS patients toIFN-β therapy (34-36).